Every day, clinicians generate thousands of reports containing critical data that will never be analysed. Not because it lacks value — but because extracting it remains a bottleneck.
Testing standardisation and optimal integration for routine clinical use remain challenging
Immunotherapy is optimising outcomes in LACC, with durable responses and long-term survival, especially in those with immune activated or ‘hot’ tumours
Long-term dostarlimab data suggest that immunotherapy may be used with curative intent in this difficult-to-treat population
In advanced or metastatic disease, bulumtatug fuvedotin shows promising efficacy and manageable safety
Recent approvals are driving a shift toward biomarker-informed treatment strategies, rational combinations and personalised sequencing
In early-phase studies, two novel agents showed low propensity to induce heamatological toxicities in heavily pre-treated solid tumours
Multi-regional modelling reveals new ways to personalise treatments in gastric and breast cancers
A manageable safety profile was also reported for pumitamig plus the antibody-drug conjugate DB-1305/BNT325 in an early-phase study
Final results from the IMPACT study support screening measures, but open questions remain
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.